{"id":"NCT05174065","sponsor":"Amgen","briefTitle":"Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-08","primaryCompletion":"2023-08-19","completion":"2024-06-01","firstPosted":"2021-12-30","resultsPosted":"2025-04-09","lastUpdate":"2025-04-09"},"enrollment":176,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Palmoplantar Pustulosis"],"interventions":[{"type":"DRUG","name":"Apremilast","otherNames":["Otezla","AMG 407"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Apremilast","type":"EXPERIMENTAL"},{"label":"Placebo and Apremilast","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Placebo-controlled Period: Placebo","deltaMin":35.3,"sd":null},{"arm":"Placebo-controlled Period: Apremilast","deltaMin":67.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":40,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":88},"commonTop":["Diarrhoea","Nasopharyngitis","Faeces soft","Nausea","Headache"]}}